Respiratory virus infections are an important cause of morbidity and mortality in bone marrow transplant patients. A retrospective study was performed on the bone marrow transplant unit at the Christie Hospital Manchester. The aim of this study was to determine the frequency, clinical presentation, laboratory diagnosis, types of intervention (eg antiviral agents used) and the outcome of such infections in this cohort of transplant recipients. Data were collected from a total of 626 adult patients and showed 27 patients with 29 confirmed episodes of viral respiratory tract infections. The viruses present were rhinovirus (40%), respiratory syncytial virus (RSV) (22.2%), influenza A (18.5%), parainfluenza (PIV) (14.8%) and enteroviruses (7.4%). The overall frequency of documented respiratory virus infections was 4.3% during the 5-year period of the study. The prevalence of respiratory viral infections was 7.8% among allogeneic and 2.3% among autologous transplant recipients. The frequency of lower respiratory tract infection (LRTI) was 3.0% among allogeneic and 1.3% among autologous transplant recipients. Eight patients died (seven had allogeneic transplants). Three of these deaths were directly attributable to a respiratory viral infection (two rhinoviruses; one PIV 3). This study further supports the role played by human respiratory viruses in transplantassociated morbidity and mortality, and particularly highlights the significance of rhinovirus infections. 1 While considerable experience has been gained regarding the role of infections with viruses such as respiratory syncytial virus (RSV), influenza A, para influenza (PIV) and adenoviruses, [2] [3] [4] there are relatively little data available regarding the role of rhinovirus infections in transplant recipients. In a recent multicentre study by the European working party, Ljungman et al 1 reported only two cases of rhinovirus infections out of a total of about 2000 patients, both mild infections. Ghosh et al 5 at the MD Anderson Cancer Centre (MDACC), Houston, Texas reported considerable morbidity and mortality associated with rhinovirus infections in myelosuppressed patients. Despite the large amount of data on the role of viral respiratory infection in BMT/SCT recipients, there is still a dearth of knowledge regarding the optimal management of these infections. We report our experience of these infections from a large retrospective study of viral respiratory infection in BMT/SCT recipients transplanted at the Adult Leukaemia Unit at the Christie Hospital NHS Trust, Manchester, UK. This unit accepts patients over the age of 18 years.
Materials and methods

Study
Computer records for five winter seasons, May 1996-May 2001, were reviewed retrospectively. Clinical respiratory viral infections confirmed by laboratory diagnosis were seen in 27 patients out of a total of 626. Herpes simplex and CMV infections were excluded from the study and no adenovirus infections were found. The medical record of each of these patients was reviewed using the case notes and computer data obtained from the Data Management Unit of Christie Hospital.
A standard proforma was used to collect patient data including age, sex, primary diagnosis, type of transplant, respiratory symptoms, specimens collected, laboratory diagnosis, intervention (eg antivirals, antibacterials, etc) and outcome of these infections.
Definitions
The following definitions were used in this study:
Upper respiratory tract infection (URTI) was defined as a positive microbiology result in a patient with symptoms of URTI (coryza, sneeze, cough, rhinorrhoea, headache, etc).
Lower respiratory tract infection (LRTI) was defined as breathlessness, hypoxia or pulmonary changes, in combination with positive microbiology from a bronchoalveolar lavage (BAL) or respiratory secretions.
Mortality was defined as death due to any cause including respiratory virus infection. Death due to a respiratory virus infection was defined as that due to respiratory failure for which no alternative cause of the pneumonia could be found.
Nasal wash samples were obtained from individuals with suspected URTI. A 5 ml syringe was used to instil saline into each nostril in turn; the saline containing nasal secretions was collected into a universal container with the patient leaning forward. Samples from LRTI included nasal wash or BAL. Sputum or BAL was also cultured for bacteria and fungi.
Specimens were transported to Manchester Public Health Laboratory where they were examined by rapid immunofluorescence for viral antigens (influenza A and B, RSV, PIV 1-4, adenovirus) (Chemicon International, Harrow) and by tissue culture in primary monkey kidney cells (CAMR, Porton Down), Hep2 cells (CAMR) and MRC5 fibroblasts (BioWhittaker UK, Wokingham) using standard methods. 6 Viruses recognized by cytopathic effect or by haemadsorption were confirmed by immunofluorescence, or, for rhinovirus, acid lability. 6 
Statistical method
The 2 Â 2 w 2 -test was used for statistical calculations to compare the frequencies of infection between patients becoming allogeneic or autologous transplants. Table 1 shows details of patient demographics, primary diagnosis and types of transplantation procedures undertaken during the study period. The mean and median ages were the same (44 years) and only three patients were over 60 years old (range 21-67 years). There was equal distribution of male and female patients. Table 2 shows the range of viruses isolated and the laboratory methods used to diagnose them.
Results
Incidence of respiratory viral infections
A total of 27 patients with 29 episodes of viral respiratory infections were found. Of these, 18 were diagnosed after allogeneic and nine after autologous transplantation. A total of 626 patients had transplants over the 5-year period of this study (approx. 125 per year). Hence, the overall frequency of documented respiratory virus infections was 4.3%. The frequency was higher in allogeneic (7.8%) than in autologous (2.3%) recipients; this was statistically significant (P ¼ 0.002).
In total 15, patients (56%) had URTI only, while 12 (44%) had both URTI and LRTI. Of those with LRTI, seven were allogeneic recipients. There was a higher frequency of LRTI amongst allogeneic transplant recipients (seven out of 230) than autologous (five out of 396).
Documented respiratory virus infections
In all, 11 patients had rhinovirus infection (six allogeneic, five autologous). Two had LRTIs only, five had URTI only while four had both URTI and LRTI. Six patients had RSV infections (five allogeneic), of whom only two had both URTI and LRTI. Five patients had an infection with influenza A (all were allogeneic) out of which four had both URTI and LRTI. Four patients had PIV 3 infection (two allogeneic; two autologous) half of them with both URTI and LRTI. Only two enteroviral infections were found (one echovirus 6, one untyped) ( Table 3 ). No significant bacterial or fungal infections were diagnosed by culture. Table 3 shows details of the viruses, their clinical presentations and outcomes. Although it is not always easy to ascertain the exact cause of death in BMT patients, with improved sampling and diagnostic techniques a few more deaths can be traced to a viral aetiology. Of eight deaths, seven were in allogeneic transplant recipients and one autologous. Two allogeneic recipients died as a direct result of their respiratory viral infection while five died from other causes.
Outcome of respiratory virus infection
Two of the 11 patients with rhinovirus infections died apparently as a direct result of their respiratory infection while another two died from other causes. Seven survived the infection without any sequelae. Of six patients diagnosed with rhinovirus LRTI two died (33%). Of nine patients with URTI at diagnosis, four progressed to pneumonia and of these two died.
Of the six patients with RSV, one died because of other causes. Of the five patients with influenza A infection (four had both URTI and LRTI), one died because of a noninfective cause. Of the four patients with PIV 3, two (50%) died-one death was directly attributable to the respiratory infection. Both patients with enteroviral infections had URTI only and survived without sequelae; one of them had a dual infection with RSV.
Antiviral agents used in the treatment
Rhinovirus infections: None of the 11 patients with infection had any active antiviral therapy. Four died -two as a result of the infection.
RSV infections: Four out of the six patients with RSV had inhaled ribavirin therapy via a SPAG nebulizer (two had both URTI and LRTI). Three patients survived and one died of a nonrespiratory cause. None of the six received immunoglobulin therapy.
Influenza A: Two of the five patients were treated for influenza A. One received oral amantadine but died of a nonrelated cause. The other was given ribavirin and survived without sequelae. None of these patients was treated with a neuraminidase inhibitor.
PIV 3: None of the four patients with PIV 3 infection had treatment with any antiviral agents. One died as a direct result of infection.
Enteroviruses: The patient with echovirus 6 infection had a dual infection with RSV and was given ribavirin. The other patient did not have any antiviral treatment. Both patients had URTI and survived.
Discussion
The role of respiratory viruses in causing severe complications following BMT/PSCT has been a subject of intense study over the last few years both in Europe and America. [1] [2] [3] Despite these efforts, there are still no national or international guidelines for the optimal management of these infections, nor is there any consensus regarding the exact incidence/prevalence, or risk factors associated with morbidity or mortality. The considerable variation in the published frequencies of viral infection in these patients is probably a reflection of a number of variables such as the degree of immunosuppression associated with different transplant protocols, level of active surveillance, sampling techniques, laboratory diagnostic methods and the prevalence of viral respiratory infection in various communities. Our study is another small step towards shedding some light into the complex issues of transplant-related viral infections.
Despite the limitations of a retrospective study and the relatively small number of respiratory virus infections present in our cohort of transplant patients, some interesting trends were identified. The frequency of these infections in both allogeneic and autologous transplant recipients in our series was lower than those reported from the United States, but consistent with studies from Europe. 1 One of the interesting things highlighted in our results is that rhinovirus was the commonest cause of infection in our patients despite the fact that reported cases of rhinovirus infections in adult transplant patients in Europe appear to be rare. 1 To the best of our knowledge, this series represents the largest number of cases of rhinovirus infections in adult BMT reported in the literature from the UK. Out of a total of 27 patients with eight deaths, 11 had rhinovirus infections of whom two died as a direct result of their LRTI while a further two died with the infection (one had disseminated toxoplasmosis as well). Considerable experience with rhinovirus infection in immunocompromised patients has been reported from the USA. 5, 7 Unlike the indolent course of the infection in most of the reports from Europe, our results are in conformity with those reported from the MD Anderson Cancer Center 5 where 32% of patients with rhinovirus infection developed fatal pneumonia. In our series, 55% (6) of the patients with rhinovirus infection developed pneumonia, two (18%) dying as a direct result. Whether human rhinovirus infection directly causes viral pneumonia in transplant recipients or predisposes to pulmonary injury and/or superinfection remains uncertain. 8, 9 However a recent report suggests that rhinoviruses can directly infect some lower respiratory tract cells. 10 Further studies on associated risk factors and the impact of new antiviral treatments (eg pleconaril) on the outcome of rhinoviral infection in transplant recipients are needed.
Only one patient with RSV infection died. The virus was contributory and not causative to the death. The good outcome of this infection is not surprising because increased awareness of RSV infection coupled with the aggressive use of ribavirin (with or without immunoglobulin) has produced a remarkable improvement in the management and subsequent outcome of RSV infection in BMT patients worldwide. [11] [12] [13] [14] [15] Of the five patients with influenza A, four (80%) developed LRTI; only one died, because of her underlying disease, with influenza A being contributory rather than the cause of death. This patient was treated with oral amantadine. A second patient received nebulized ribavirin and recovered without any sequelae. We could not establish from the case records whether the remaining two patients with LRTIs had any antiviral therapy, but both of them also survived the infection. This seems a favourable outcome of influenza A infection. Although the risk factors for influenza have not been clearly defined, studies from both Europe 1, 3 and America 16 seem to suggest a mortality of about 17%. The favourable outcome in our series may be partly explained by the younger age of our patients (mean age 44 years), and the fact that some of them may have been protected through our proactive vaccination policy; vaccination is offered to staff and to the families of transplant patients. Vaccine is also offered to patients from 12 months post-transplant. However, response to vaccination is often poor in patients with haematological disease. 17 Four patients had infection with PIV 3. Of two (50%) who developed pneumonitis one died directly from the infection while the second died because of graft-versus-host disease with PIV3 being contributory. The fact that PIVs are important causes of life-threatening pneumonia in adult BMT recipients, especially those who have recently undergone allogeneic transplantation, is well known. 2, 3, 18 Mortality in this series is comparable to the reports in the literature. 18 Only two cases of enteroviruses were found; both had URTI only and recovered. The picornaviruses, which include both rhinoviruses and enteroviruses have long been associated with URTI in nonimmunocompromised patients. 19 Whether these groups of viruses are a significant cause of LRTI in immunocompromised patients is yet to be studied extensively. A report from Houston, Texas shows that 18% of community-acquired respiratory infections in BMT patients were due to picornaviruses (490% rhinoviruses). 20 Finally, the results of this retrospective study have again highlighted the importance of viral respiratory infection in causing morbidity and mortality in transplant recipients. While RSV, influenza and parainfluenza viruses are recognized causes of complications in these patients, the contribution of rhinoviruses in transplant recipients may have been underestimated. Development of improved diagnostic techniques for respiratory agents including rhinoviruses, for example PCR, 21 and the potential introduction of new antiviral agents with activity against rhinoviruses such as oral pleconaril (WIN 63843) 22 and intranasal ruprintrivir 23 should be incentives for further studies. Awareness of the risk posed by all these viruses is important, but defining effective prophylactic and therapeutic strategies will be a challenge that needs to be studied in controlled trials.
